Translate the text from Welsh to English.



 
‌‌Heddiw, yn rhan o'i adolygiad diweddaraf ar raglen frechu COVID\-19, mae'r Cyd\-bwyllgor ar Imiwneiddio a Brechu wedi cyhoeddi datganiad sy'n argymell brechiad atgyfnerthu y gwanwyn ar gyfer y bobl hynny y mae'n ystyried y byddent yn elwa fwyaf ar gael eu brechu.

Prif nod rhaglen frechu COVID\-19 o hyd yw atal clefydau difrifol (sy'n arwain at orfod mynd i'r ysbyty a marwolaethau) yn sgil COVID\-19\. Fel strategaeth ragofalus, mae'r Cyd\-bwyllgor wedi argymell y dylai'r bobl a ganlyn gael dos atgyfnerthu yn y gwanwyn:

* **oedolion 75 oed a throsodd;**
* **pobl sy’n byw mewn cartref gofal i oedolion hŷn, ac**
* **unigolion 6 mis oed a throsodd sy'n imiwnoataledig (fel y'i diffinnir yn nhabl 3 neu 4 yn y****Llyfr Gwyrdd****).**‌

Wrth argymell hyn, mae'r Cyd\-bwyllgor wedi ystyried y data sydd ar gael yn y DU ac yn rhyngwladol, sy'n parhau i awgrymu mai pobl hŷn sy'n wynebu'r risg uchaf o gael clefydau difrifol os cânt eu heintio gan COVID\-19\. Mae'r Pwyllgor hefyd wedi nodi y dylid cynnig dos y gwanwyn tua 6 mis ar ôl y dos brechlyn diwethaf, er y caniateir hyblygrwydd gweithredol o ran yr amseriad.  Ystyrir mai'r brechlynnau COVID\-19 amrywiolyn XBB diweddaraf, sy'n cyfateb agosaf at yr amrywiolion sy'n lledaenu ar hyn o bryd, sydd orau i'w defnyddio ar gyfer yr ymgyrch.  Dyma'r brechlynnau Pfizer\-BioNTech a Moderna mRNA XBB.1\.5\.

Rwyf wedi derbyn y cyngor hwn ac mae cais wedi'i wneud i fyrddau iechyd gynllunio eu rhaglenni brechiadau atgyfnerthu y gwanwyn ar y sail hon. Bydd manylion y rhaglen yn cael eu nodi yn fuan mewn rhifyn o Gylchlythyr Iechyd Cymru a gyhoeddir gan y Prif Swyddog Meddygol.

Fel ag erioed, rwy'n ddiolchgar iawn i'r GIG ac i bawb sy'n ymwneud â'r rhaglen frechu am eu gwaith caled parhaus i helpu i gadw'r rhai mwyaf agored i niwed yn ein cymunedau yn ddiogel ac wedi'u hamddiffyn.







Translation:


 
The Joint Committee on Vaccination and Immunisation (JCVI), as part of its latest review of the COVID\-19 vaccination programme, has today published a statement recommending a spring booster for those citizens it considers would benefit most from being vaccinated.

The primary aim of the COVID\-19 vaccination programme continues to be the prevention of severe disease (hospitalisation and mortality) arising from COVID\-19\. The Committee has recommended, as a precautionary strategy, a booster dose in the spring for:

* **adults aged 75 years and over;**
* **residents in a care home for older adults, and**
* **individuals aged 6 months and over who are immunosuppressed (as defined in table 3 or 4 in the****Green Book****).**

In making this recommendation, the JCVI has considered available data from the UK and internationally, which continues to suggest older people are at the highest risk of experiencing severe disease if infected by COVID\-19\. The Committee has also stated that the spring dose should be offered around 6 months after the last vaccine dose, although operational flexibility around the timing is allowed.  The latest COVID\-19 XBB\-variant vaccines, which most closely match currently circulating variants, are considered preferable for use in the campaign.  These are the Pfizer\-BioNTech and Moderna mRNA XBB.1\.5 vaccines.

I have accepted this advice and health boards have been asked to plan their spring booster programmes on this basis.  The details of the programme will be set out imminently in a Welsh Health Circular issued by the Chief Medical Officer.

As ever, I am extremely grateful to the NHS and everyone involved in the vaccination programme for their continued hard work to help keep the most vulnerable in our communities safe and protected.